Stockholder's Equity

9 Months Ended

Sep. 30, 2025

Share-Based Payment Arrangement, Noncash Expense [Abstract]

(a) Stock Equity and Incentive Plan

The Company recognizes stock-based compensation in accordance with the provisions of ASC Topic 718, Compensation-Stock Compensation. Stock-based compensation expense was $367 and $384, excluding $(1) and $1 of compensation expense related to our Amended and Restated 1996 Employee Stock Purchase Plan, or the ESPP, for the three months ended September 30, 2025 and 2024, respectively, and $1,134 and $1,622, excluding $3 and $7 of compensation expense related to ESPP, for the nine months ended September 30, 2025 and 2024, respectively. As of September 30, 2025, there was $1,708 of total unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.87 years. As of September 30, 2025, there was $1,117 of total unrecognized compensation expense related to restricted stock awards, which is expected to be recognized over a weighted-average period of 1.52 years.

Stock Options

During the three months ended September 30, 2025, no shares of common stock were issued upon the exercise of stock options. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the three months ended September 30, 2025, no stock options were granted and 132 stock options expired, were canceled or were forfeited. During the three months ended September 30, 2024, no shares of common stock were issued upon the exercise of stock options. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the three months ended September 30, 2024, no stock options were granted and 230 stock options expired, were canceled or were forfeited.

During the nine months ended September 30, 2025, 6 shares of common stock were issued upon the exercise of stock options. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the nine months ended September 30, 2025, 575 stock options were granted and 259 stock options expired, were canceled or were forfeited. During the nine months ended September 30, 2024, no shares of common stock were issued upon the exercise of stock options. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the nine months ended September 30, 2024, 266 stock options were granted and 501 stock options expired, were canceled or were forfeited. The Company has historically estimated the fair value of each option grant on the date of grant using the Black-Scholes option-pricing model. The weighted average assumptions utilized to determine the fair value of options granted during the nine months ended September 30, 2025 and 2024 are as follows:



	Nine Months Ended September 30,
	2025		2024
Risk-free interest rate	3.93	%	4.36	%
Expected volatility	40.81	%	48.63	%
Expected life (in years)	3.77		4.32
Dividend yield	0	%	0	%

As of September 30, 2025, there were 1,264 options outstanding with a weighted average exercise price of $7.09 per share and 380 options exercisable with a weighted average exercise price of $9.22 per share. As of September 30, 2024, there were 995 options outstanding with a weighted average exercise price of $8.23 per share and 410 options exercisable with a weighted average exercise price of $9.32 per share.

Restricted Stock

During the three months ended September 30, 2025, 70 shares of restricted stock were granted with a weighted average grant date fair value of $5.50 per share and 4 shares of restricted stock were forfeited. Additionally, during the three months ended September 30, 2025, 1 shares of restricted stock vested. During the three months ended September 30, 2024, 85 shares of restricted stock were granted with a weighted average grant date fair value of $4.51 per share and no share of restricted stock were forfeited. Additionally, during the three months ended September 30, 2024, 16 shares of restricted stock vested.

During the nine months ended September 30, 2025, 70 shares of restricted stock were granted with a weighted average grant date fair value of $5.50 per share and 26 shares of restricted stock were forfeited. Additionally, during the nine months ended September 30, 2025, 147 shares of restricted stock vested. During the nine months ended September 30, 2024, 207 shares of restricted stock were granted with a weighted average grant date fair value of $4.82 per share and 43 shares of restricted stock were forfeited. Additionally, during the nine months ended September 30, 2024, 158 shares of restricted stock vested.

As of September 30, 2025 and 2024, the Company had no unvested outstanding options and no outstanding shares of restricted stock that were subject to performance-based or market-based vesting conditions.

(b) Employee Stock Purchase Plan

The Company's ESPP affords eligible employees the right to purchase common stock, via payroll deductions, through various offering periods at a purchase price equal to 85% of the fair market value of the common stock on the first or last day of the offering period, whichever is lower. During the three months ended September 30, 2025 and 2024, 4 and 0 shares were issued under the ESPP, respectively. During the nine months ended September 30, 2025 and 2024, 4 and 24 shares were issued under the ESPP, respectively. The Company recorded compensation charges related to the ESPP of $(1) and $1 for the three months ended September 30, 2025 and 2024, respectively, and $3 and $7 for the nine months ended September 30, 2025 and 2024, respectively.

The following table presents stock-based compensation expense, including expense for the ESPP, in the Company's consolidated statements of operations for the nine months ended September 30, 2025 and 2024, respectively:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Cost of service sales	$	6	$	8	$	19	$	22
Cost of product sales	12		5		22		19
Research and development	15		63		7		326
Sales, marketing and support	61		74		215		219
General and administrative	272		235		874		1,043
	$	366	$	385	$	1,137	$	1,629

(d) Accumulated Other Comprehensive Loss (AOCL)

Comprehensive income (loss) includes net income (loss), unrealized gains and losses from foreign currency translation, and unrealized gains and losses on available for sale marketable securities. The components of the Company’s comprehensive income (loss) and the effect on earnings for the periods presented are detailed in the accompanying consolidated statements of comprehensive income (loss).

The balances for the three months ended September 30, 2025 and 2024 are as follows:




	Foreign Currency Translation		Total Accumulated Other Comprehensive Loss
Balance, June 30, 2025	$	(3,032)	$	(3,032)
Other comprehensive loss	(676)		(676)
Net other comprehensive loss	(676)		(676)
Balance, September 30, 2025	$	(3,708)	$	(3,708)




	Foreign Currency Translation		Total Accumulated Other Comprehensive Loss
Balance, June 30, 2024	$	(3,991)	$	(3,991)
Other comprehensive income	134		134

Net other comprehensive income	134		134
Balance, September 30, 2024	$	(3,857)	$	(3,857)

The balances for the nine months ended September 30, 2025 and 2024 are as follows:



	Foreign Currency Translation		Total Accumulated Other Comprehensive Loss
Balance, December 31, 2024	$	(4,032)	$	(4,032)
Other comprehensive income	324		324
Net other comprehensive income	324		324
Balance, September 30, 2025	$	(3,708)	$	(3,708)



	Foreign Currency Translation		Total Accumulated Other Comprehensive Loss
Balance, December 31, 2023	$	(4,185)	$	(4,185)
Other comprehensive income	328		328

Net other comprehensive income	328		328
Balance, September 30, 2024	$	(3,857)	$	(3,857)